Relevium Launches Bioganix® on Walmart.com   


MONTREAL, May 03, 2018 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V:RLV) (OTCQB:RLLVF) (Frankfurt:6BX) (the “Company or Relevium”), is pleased to announce that it has received approval to sell its biggest mover Bioganix® products on Walmart.com.

Highlights

  • New and diverse revenue channel with over 400M monthly visitors
  • Onboarding and approval to Walmart.com is complete
  • Sales testing of Bioganix® products is currently online
  • Bioganix® will launch best selling SKUs and customize a new offering for a new demographic
  • Opens a new sales vertical and mitigates channel risk

Walmart.com will provide Relevium with access to 400M new visitors per month with a diverse customer demographic and profile. According to CBS MoneyWatch, Walmart.com shoppers are primarily young women and nearly half have families with kids and a diverse ethnic profile. Amazon and Walmart demographics are complementary thereby mitigating channel risk for the Bioganix® brand.

Aurelio Useche, CEO of Relevium stated: “The addition of the Walmart.com platform to the existing Amazon.com sales channel gives Bioganix® a new and diverse audience and should prove to be accretive to revenues going forward.” Mr. Useche continued: “Diversifying our sales channels also de-risks the reliance on individual marketplaces and allows us to reach new customers across the USA, Europe and Asia. This is a major step for the Company and our expectations are high.”

Abis Hussain, SMO of Relevium, stated: “The Operations Team has concluded that the audience and the competition on Walmart.com is very different than those in Amazon.com and should reflect nicely on the bottom line for the Company. As an added bonus, Walmart.com will be key to the introduction of full spectrum hemp oil products, which will prove to be extremely valuable going forward as we prepare to launch products related to the space.”   

Bioganix® products have been available on the Walmart.com platform, on a test-basis, for sale and delivery in the United States of America as of May 1, 2018. Initially, the Company will be offering five (5) to eight (8) of its best-selling products on the platform and then evaluate which products will subsequently be made available.

Relevium has the intention of selling products from its current catalogue as well as new products that will be launched in 2018. New products will be centered around major themes in the health and wellness markets including weight management, sports performance, ketogenic diets and general well being offered through hemp-derived products.

Bioganix® products will now be widely available in the USA through Bioganix.com, Amazon.com and Walmart.com and imminently in the United Kingdom through Amazon.co.uk.

About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or "occur". Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will be able to apply for and ultimately obtain an ACMPR licence, the proposed business of Biocannabix will develop as anticipated, that the Company will raise sufficient funds to develop the Biocannabix business, and that the Company will obtain all requisite regulatory approvals. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed business developments may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.

On Behalf of the Board of Directors

RELEVIUM TECHNOLOGIES INC.

Aurelio Useche
President and CEO

For more information about this press release:

Tel: +1.888.528.8687

RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Like us on Facebook
Follow us on Twitter
Follow us on LinkedIn